- $231.78m
- $106.61m
Brief: Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
Palisade Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Palisade Bio Inc Files For Resale Of Up To 1.6 Million Shares By The Selling Stockholders - SEC Filing
Palisade Bio Inc expected to post a loss of $4.80 a share - Earnings Preview
Brief: Palisade Bio Announces Closing Of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Brief: Palisade Bio Got Notice From Nasdaq That Company Was Not In Compliance With Audit Committee Requirements
Palisade Bio Inc reports results for the quarter ended in December - Earnings Summary
Palisade Bio Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Palisade Bio Provides Corporate Update And Reiterates Guidance
Brief: Palisade Bio Announces Formation Of Clinical Advisory Board
U.S. STOCKS ON THE MOVE-Sarepta, Hershey, Dollar Tree
U.S. STOCKS ON THE MOVE-Overseas Shipholding, Palisade Bio, Archer-Daniels-Midland
Palisade Bio more than doubles as bowel disease therapy shows promise in lab studies
Palisade Bio surges as bowel disease therapy shows promise in lab studies
Brief: Palisade Bio Files For Offering Of Shares Of Common Stock Size Not Disclosed
Brief: Palisade Bio Q3 EPS USD -0.49
Brief: Palisade Bio Appoints GI Clinical Expert Mitchell Jones As Chief Medical Officer
U.S. STOCKS ON THE MOVE-Comcast, Apple, Lockheed Martin
U.S. STOCKS ON THE MOVE-Applied Therapeutics, Salesforce, Palisade Bio